Market Price & Insight
Production and sales statistics of erythromycin and other APIs of Zhejiang Guobang Pharmaceutical from 2018 to 2020
Azithromycin More Market Insights
-
Entreprise Dynamic
Inner Mongolia Jiupeng Pharmaceutical Co., Ltd. invested 1 billion yuan in the third phase of the construction of azithromycin, tetracycline and other API projects -
Special Report
Zhejiang Guobang Pharmaceutical and Jiangsu Kaiyuan Pharmaceutical signed a strategic cooperation agreement
Recommend Products
-
![Buy N-[(1R,7R)-9,9-Dimethyl-2,2,6,6-tetraphenyl-3,5,8,10-tetraoxa-4-phosphabicyclo[5.3.0]decan-4-yl]dibenzo[b,f]azepine]( "N-[(1R,7R)-9,9-Dimethyl-2,2,6,6-tetraphenyl-3,5,8,10-tetraoxa-4-phosphabicyclo[5.3.0]decan-4-yl]dibenzo[b,f]azepine")
N-[(1R,7R)-9,9-Dimethyl-2,2,6,6-tetraphenyl-3,5,8,10-tetraoxa-4-phosphabicyclo[5.3.0]decan-4-yl]dibenzo[b,f]azepine
Cas No.: 1092695-14-1
HENAN OWESOME PHARMECEUTICAL TECHNOLOGY
-
![Buy 6-Methoxy-3- quinolinecarboxvlic acid]( "6-Methoxy-3- quinolinecarboxvlic acid")
-
![Buy ETHYL 2-CHLORO-6-HYDROXYBENZOATE]( "ETHYL 2-CHLORO-6-HYDROXYBENZOATE")
![Buy N-[(1R,7R)-9,9-Dimethyl-2,2,6,6-tetraphenyl-3,5,8,10-tetraoxa-4-phosphabicyclo[5.3.0]decan-4-yl]dibenzo[b,f]azepine](https://file.echemi.com/fileManage/upload/goodpicture/20221227/m20221227163650566.jpg "N-[(1R,7R)-9,9-Dimethyl-2,2,6,6-tetraphenyl-3,5,8,10-tetraoxa-4-phosphabicyclo[5.3.0]decan-4-yl]dibenzo[b,f]azepine")
Breaking News
-
Benzene Weekly Report (October 05, 2026 - October 11, 2026)
Oct 12 -
Styrene Weekly Report (October 05, 2026 - October 11, 2026)
Oct 12 -
[Aniline]: Supply tightening and cost support continue to strengthen, aniline high pattern is difficult to break (2026-10-15)
Oct 15 -
[PE]: China LDPE USD Market Price on October 10, 2026
Oct 10 -
Aniline Weekly Report (October 05, 2026 - October 11, 2026)
Oct 12 -
Caprolactam Weekly Report (October 05, 2026 - October 11, 2026)
Oct 12
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)